A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
Marc Ferrante 1
Valerie Pivorunas 2
James Butler 3
Naim Mahi 3
Nael M. Mostafa 3
Melanie Ruzek 2
James Fann 2
Feng Hong 4
Xiaohong Cao
Nizar Smaoui
Justin Wade Davis
Jasmina Kalabic
Alexandra Song
Heath M. Guay
Florian Rieder
Julian Panés
Jean-Frédéric Colombel
1 University Hospitals Leuven,KU Leuven,Belgium
2 AbbVie Bioresearch Center,Worcester,United States
3 AbbVie Inc.,North Chicago,United States
4 AbbVie Bior
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]